News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,765 Results
Type
Article (13641)
Company Profile (108)
Press Release (249016)
Section
Business (87977)
Career Advice (464)
Deals (15333)
Drug Delivery (64)
Drug Development (36552)
Employer Resources (49)
FDA (6270)
Job Trends (6189)
News (150092)
Policy (14016)
Tag
Academia (435)
Alliances (23168)
Alzheimer's disease (370)
Approvals (6280)
Artificial intelligence (72)
Bankruptcy (144)
Best Places to Work (4355)
Breast cancer (64)
Cancer (447)
Cardiovascular disease (46)
Career advice (406)
Cell therapy (60)
Clinical research (30618)
Collaboration (229)
Compensation (96)
COVID-19 (751)
C-suite (74)
Data (446)
Diabetes (64)
Diagnostics (1246)
Drug discovery (45)
Drug pricing (59)
Earnings (31629)
Events (37015)
Executive appointments (255)
FDA (6531)
Funding (151)
Gene therapy (72)
GLP-1 (313)
Government (1272)
Healthcare (3542)
Infectious disease (773)
Inflammatory bowel disease (50)
Interviews (58)
IPO (5846)
Job creations (2050)
Job search strategy (372)
Layoffs (170)
Legal (3416)
Lung cancer (63)
Manufacturing (112)
Medical device (1265)
Medtech (1267)
Mergers & acquisitions (9586)
Metabolic disorders (198)
Neuroscience (492)
NextGen: Class of 2025 (1581)
Non-profit (591)
Northern California (545)
Obesity (118)
Opinion (113)
Patents (69)
People (28633)
Pharmaceutical (67)
Phase I (7972)
Phase II (12944)
Phase III (11631)
Pipeline (230)
Policy (47)
Postmarket research (1400)
Preclinical (3180)
Radiopharmaceuticals (116)
Rare diseases (115)
Real estate (2632)
Regulatory (9926)
Research institute (563)
Resumes & cover letters (55)
Southern California (527)
Startups (1625)
United States (5297)
Vaccines (120)
Weight loss (86)
Date
Last 7 days (241)
Last 30 days (707)
Last 365 days (12361)
2025 (572)
2024 (12509)
2023 (14249)
2022 (19558)
2021 (20070)
2020 (19034)
2019 (14886)
2018 (11713)
2017 (13891)
2016 (13130)
2015 (15497)
2014 (12423)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (312)
Arizona (45)
Asia (19959)
Australia (2572)
California (1266)
Canada (713)
China (167)
Colorado (51)
Connecticut (54)
Europe (39010)
Florida (208)
Illinois (145)
Indiana (103)
Japan (59)
Kansas (53)
Maryland (185)
Massachusetts (1103)
Minnesota (70)
New Jersey (527)
New York (357)
North Carolina (313)
Northern California (545)
Pennsylvania (336)
South America (500)
Southern California (527)
Texas (167)
Virginia (49)
Washington State (85)
262,765 Results for "yamo pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
July 30, 2024
·
4 min read
Drug Development
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
Yamo Pharmaceuticals LLC, a clinical stage pharmaceutical company, announced that it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder.
November 20, 2023
·
5 min read
Drug Development
As Autism Cases Rise, Biopharma Springs Into Action
Several companies—including Roche, Curemark and Yamo Pharmaceuticals—are running clinical trials of treatments that aim to offset the myriad challenges of autism.
April 25, 2024
·
6 min read
·
Tyler Patchen
Business
Yamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals, LLC announced that The Autism Impact Fund has made a capital investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD.
November 10, 2021
·
3 min read
Drug Development
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals today announced that the first patient has been treated in a Phase 2 study of L1-79 in adolescents and young adults with ASD at six U.S. research centers of excellence.
January 27, 2022
·
4 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
January 14, 2025
·
6 min read
Press Releases
Olympia Pharmaceuticals Announces the Launch of Sister Brand, Wesley Pharmaceuticals, in Honor of Beloved Employee
December 18, 2024
·
3 min read
Drug Development
Yamo Pharmaceuticals Presents Results from Phase 2 Study of L1-79 in Adolescents and Young Adult Males with Autism Spectrum Disorder at INSAR 2019
Yamo Pharmaceuticals, LLC announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD.
May 15, 2019
·
3 min read
Press Releases
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 27, 2024
·
1 min read
1 of 26,277
Next
